AIMS: To determine whether lower umbilical cord than maternal binding of indinavir and saquinavir contributed to the low cord : maternal (C : M) total concentration ratios reported previously. METHODS: Indinavir and saquinavir unbound fraction (fu) was determined using equilibrium dialysis. Buffer solutions of human serum albumin (HSA) (20.0, 30.0, 40.0 g l(-1)) and alpha(1)-acid glycoprotein (AAG) (0.20, 0.60, 2.00 g l(-1)) were spiked with indinavir (1.00 and 8.00 mg l(-1)) or saquinavir (0.15 and 1.50 mg l(-1)). Matched maternal and umbilical cord plasma was spiked with 1.00 mg l(-1) indinavir (n = 12) or 0.15 mg l(-1) saquinavir (n = 20). Spiked protein/plasma solutions were dialyzed against isotonic phosphate buffer, at 37 degrees C. At equilibrium, indinavir and saquinavir concentrations were quantified, and the f(u) determined. RESULTS: Indinavir and saquinavir demonstrated protein concentration-dependent binding in buffer solutions of HSA and AAG. Indinavir f(u) was significantly higher in umbilical cord (0.53 +/- 0.12) compared with maternal (0.36 +/- 0.11) plasma (95% CI of the difference -0.26, -0.097). Similarly, saquinavir fu was different between umbilical cord (0.0090 +/- 0.0046) and maternal plasma (0.0066 +/- 0.0039) (95% CI of the difference -0.0032, -0.0016). The transplacental AAG concentration gradient contributed significantly to the binding differential of both drugs. CONCLUSIONS: The differential plasma binding of both drugs, which was largely the result of the transplacental AAG concentration gradient, would contribute to the low C : M total plasma concentration ratios observed previously. Unbound concentrations of indinavir and saquinavir are likely to be substantially lower in umbilical cord than maternal plasma.
AIMS: To determine whether lower umbilical cord than maternal binding of indinavir and saquinavir contributed to the low cord : maternal (C : M) total concentration ratios reported previously. METHODS:Indinavir and saquinavir unbound fraction (fu) was determined using equilibrium dialysis. Buffer solutions of humanserum albumin (HSA) (20.0, 30.0, 40.0 g l(-1)) and alpha(1)-acid glycoprotein (AAG) (0.20, 0.60, 2.00 g l(-1)) were spiked with indinavir (1.00 and 8.00 mg l(-1)) or saquinavir (0.15 and 1.50 mg l(-1)). Matched maternal and umbilical cord plasma was spiked with 1.00 mg l(-1) indinavir (n = 12) or 0.15 mg l(-1) saquinavir (n = 20). Spiked protein/plasma solutions were dialyzed against isotonic phosphate buffer, at 37 degrees C. At equilibrium, indinavir and saquinavir concentrations were quantified, and the f(u) determined. RESULTS:Indinavir and saquinavir demonstrated protein concentration-dependent binding in buffer solutions of HSA and AAG. Indinavir f(u) was significantly higher in umbilical cord (0.53 +/- 0.12) compared with maternal (0.36 +/- 0.11) plasma (95% CI of the difference -0.26, -0.097). Similarly, saquinavir fu was different between umbilical cord (0.0090 +/- 0.0046) and maternal plasma (0.0066 +/- 0.0039) (95% CI of the difference -0.0032, -0.0016). The transplacental AAG concentration gradient contributed significantly to the binding differential of both drugs. CONCLUSIONS: The differential plasma binding of both drugs, which was largely the result of the transplacental AAG concentration gradient, would contribute to the low C : M total plasma concentration ratios observed previously. Unbound concentrations of indinavir and saquinavir are likely to be substantially lower in umbilical cord than maternal plasma.
Authors: Rolf P G van Heeswijk; Yasmin Khaliq; Keith D Gallicano; Marc Bourbeau; Isabelle Seguin; Elizabeth J Phillips; D William Cameron Journal: Clin Pharmacol Ther Date: 2004-12 Impact factor: 6.875
Authors: Sreeja Sudhakaran; Hany Ghabrial; Roger L Nation; David C M Kong; Neil M Gude; Peter W Angus; Craig R Rayner Journal: Antimicrob Agents Chemother Date: 2005-03 Impact factor: 5.191
Authors: C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey Journal: Biochemistry Date: 1998-03-17 Impact factor: 3.162
Authors: A Molla; S Vasavanonda; G Kumar; H L Sham; M Johnson; B Grabowski; J F Denissen; W Kohlbrenner; J J Plattner; J M Leonard; D W Norbeck; D J Kempf Journal: Virology Date: 1998-10-25 Impact factor: 3.616
Authors: C Vinot; L Gavard; J M Tréluyer; S Manceau; E Courbon; J M Scherrmann; X Declèves; D Duro; G Peytavin; L Mandelbrot; C Giraud Journal: Antimicrob Agents Chemother Date: 2013-01-07 Impact factor: 5.191
Authors: Andrea L Gordon; Olga V Lopatko; Andrew A Somogyi; David J R Foster; Jason M White Journal: Br J Clin Pharmacol Date: 2010-12 Impact factor: 4.335
Authors: Pierre-Francois Ceccaldi; Laurent Gavard; Laurent Mandelbrot; Elisabeth Rey; Robert Farinotti; Jean-Marc Treluyer; Sophie Gil Journal: Obstet Gynecol Int Date: 2009-05-18
Authors: Ana P Costa; Michael H Court; Nicolas F Villarino; Neal S Burke; Katrina L Mealey Journal: J Vet Pharmacol Ther Date: 2020-08-03 Impact factor: 1.786